Literature DB >> 24139845

Trisubstituted and tetrasubstituted pyrazolines as a novel class of cell-growth inhibitors in tumor cells with wild type p53.

Mohammad Abdel-Halim1, Adam B Keeton, Evrim Gurpinar, Bernard D Gary, Simon M Vogel, Matthias Engel, Gary A Piazza, Frank M Boeckler, Rolf W Hartmann, Ashraf H Abadi.   

Abstract

Derivatives with scaffolds of 1,3,5-tri-substituted pyrazoline and 1,3,4,5-tetra-substituted pyrazoline were synthesized and tested for their inhibitory effects versus the p53(+/+) HCT116 and p53(-/-) H1299 human tumor cell lines. Several compounds were active against the two cell lines displaying IC50 values in the low micromolar range with a clearly more pronounced effect on the p53(+/+) HCT116 cells. The compound class shows excellent developability due to the modular synthesis, allowing independent optimization of all three to four key substituents to improve the properties of the molecules.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anticancer; Pyrazoline; p53

Mesh:

Substances:

Year:  2013        PMID: 24139845     DOI: 10.1016/j.bmc.2013.09.055

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  1 in total

1.  Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors.

Authors:  Mohammad Abdel-Halim; Heather Tinsley; Adam B Keeton; Mohammed Weam; Noha H Atta; Mennatallah A Hammam; Amr Hefnawy; Rolf W Hartmann; Matthias Engel; Gary A Piazza; Ashraf H Abadi
Journal:  Bioorg Chem       Date:  2020-09-28       Impact factor: 5.275

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.